The Number Most CFOs Don't Know
Your pharmacy spend is climbing. You feel it at renewal. But most CFOs still don't know how much of that bill is one drug category.
According to Aon via SHRM, GLP-1 drugs now make up roughly 20% of total prescription drug costs for employers. Spend jumped another 50% in 2025 alone. For some plans, especially those with liberal coverage policies, the share is closer to 25%.
If you don't know your number, you're flying blind into the most expensive benefits decision of the decade.
How Fast This Is Moving
The growth isn't a trend anymore. It's a structural shift. KFF reports gross Medicare Part D spending on GLP-1s hit $27.5 billion in 2024, a five-fold increase from 2019.
Employer plans are tracking the same curve. Self-insured employers offering GLP-1 coverage for obesity saw more than a ten-fold increase in per-member, per-month costs from January 2023 to December 2024, according to an ICER White Paper published in April 2025. That's not a rounding error.
Blue Cross Blue Shield of Massachusetts spent over $300 million on GLP-1s in 2024, double the prior year. They ended the year with a $400 million operating loss, its worst on record. That's what unchecked utilization looks like at scale.
Cover, Exclude, or Manage: The Three Paths
Only 33% of health plans and employers surveyed covered GLP-1s for obesity as of July 2024, based on a Pharmaceutical Strategies Group employer survey. That number is growing. And so is employee demand.
A Statista Consumer Insights survey from early 2026 found 1 in 8 Americans now use GLP-1 drugs for weight loss. Over 26% combined describe them as legitimate for chronic disease or as a next step when lifestyle changes fail. Your employees are forming opinions, whether or not your plan covers it.
Here's what each path actually costs you.
| Approach | Avg. Net PMPM | Utilization Risk | Retention Risk |
|---|---|---|---|
| Full coverage, no guardrails | $700–$800 | High | Low |
| Coverage with clinical mgmt. | $300–$500 est. | Moderate | Low |
| Blanket exclusion | $0 direct | None | High |
Net cost after rebates and discounts averages $700 to $800 per member per month, per a PMC fiscal impact study. Novo Nordisk itself reported rebates and fees account for about 40% of Ozempic and Wegovy's cost.
Rebates matter, but they don't close the gap alone. Blanket exclusion looks cheap on paper. It isn't free. You trade direct pharmacy cost for turnover risk, competitive disadvantage, and potential downstream medical spend on conditions obesity drives.
Clinical Management: The Middle Path That Actually Works
You don't have to choose between unlimited coverage and a hard no. Most mid-market employers who get this right are using a layered approach.
- Require a confirmed obesity or type 2 diabetes diagnosis before coverage activates, not just a BMI threshold.
- Mandate enrollment in a concurrent lifestyle or disease management program. Many stop-loss carriers now require this anyway.
- Build in step therapy so members try lower-cost options first when clinically appropriate.
- Set quantity limits and require periodic reassessment, typically every 6 to 12 months, to confirm continued clinical response.
- Carve out pharmacy to a transparent PBM so you actually see your rebate dollars and net cost per claim.
Geography matters too. The AMA published data showing GLP-1 spending per capita ranged from $918 in New York to $267 in Oregon. If your workforce is concentrated in high-utilization states, your exposure is higher than the national average suggests. Pull your own claims data and check.
Overall prescription drug costs are rising 13 to 15% annually, with GLP-1s fueling much of that growth. Drugs now account for roughly 30% of total employer healthcare costs. That means your pharmacy strategy belongs in the same room as your stop-loss renewal.
The Question You Need to Answer Before Your Next Renewal
Pull your pharmacy claims. Find your GLP-1 spend as a percentage of total drug costs. If you don't have access to that data, that's the first problem to fix.
Clinical management works. Blanket denial creates legal exposure, turnover, and a message to your workforce that chronic disease isn't worth covering. But coverage without guardrails will break your pharmacy budget inside 24 months.
You don't need a perfect policy. You need a defensible one, built on your actual numbers, not the national average.